ProCE Banner Activity

Optimizing the Use of PARP Inhibitors for the Treatment of Patients With Ovarian Cancer

Slideset Download
Download this slideset covering the latest data on the use of PARP inhibitors to optimize outcomes for patients with ovarian cancer.

Released: December 13, 2019

Expiration: December 11, 2020

No longer available for credit.

Share

Faculty

Prof Isabelle Ray-Coquard

Prof Isabelle Ray-Coquard, MD, PhD

President of the Gineco Group
Centre Leon Bérard
Laboratoire RESHAPE u1290
Université Claude Bernard Lyon Est
Lyon, France

Ignace Vergote

Ignace Vergote, MD, PhD

Professor Em. of Department of Obstetrics and Gynecologic Oncology
University Hospitals Leuven Belgium

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Prof Isabelle Ray-Coquard, MD, PhD

President of the Gineco Group
Centre Leon Bérard
Laboratoire RESHAPE u1290
Université Claude Bernard Lyon Est
Lyon, France

Isabelle Ray Coquard, MD, PhD, has disclosed that she has received consulting fees from AstraZeneca, Clovis, Genmab PharmaMar, Roche, and Tesaro, and fees for non-CME/CE services from AstraZeneca, Clovis, PharmaMar, and Tesaro.

Ignace Vergote, MD, PhD

Professor Em. of Department of Obstetrics and Gynecologic Oncology
University Hospitals Leuven Belgium

Ignace Vergote, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Biocad, Immunogen, Merck, MSD, PharmaMar, Roche, Sotio, and Tesaro/GSK, and funds for research support from Amgen, AstraZeneca, and Roche.